Atrial fibrillation drugs get committee review
Executive Summary
FDA's Cardio-Renal Drugs Advisory Committee will review two new chemical entities for acute conversion of atrial fibrillation Dec. 11-12, Cardiome/Astellas' vernakalant and Solvay's Pulzium (tedisamil), according to Cardiome. The meeting date comes after vernakalant's user fee date, necessitating a three-month user fee extension to Jan. 19. Executives at Cardiome indicated the decision was likely due to the agency's decision to put Solvay's competing product - submitted months after the NDA for vernakalant had been filed - under an advisory committee review. Cardiome submitted its NDA for an intravenous version of vernakalant in December, while Solvay announced its NDA filing for an IV Pulzium formulation in April...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.